Overview

An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand

Status:
Completed
Trial end date:
2009-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Naxagolide